Cargando…

Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials

Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumoulin, Daphne W., Cornelissen, Robin, Bezemer, Koen, Baart, Sara J., Aerts, Joachim G. J. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158710/ https://www.ncbi.nlm.nih.gov/pubmed/34069348 http://dx.doi.org/10.3390/vaccines9050525

Ejemplares similares

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
por: Noordam, Lisanne, et al.
Publicado: (2018)

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
por: Minnema-Luiting, Jorien, et al.
Publicado: (2018)

Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours
por: Dumoulin, Daphne W., et al.
Publicado: (2023)

T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
por: Vroman, Heleen, et al.
Publicado: (2020)

New Roads Open Up for Implementing Immunotherapy in Mesothelioma
por: Cornelissen, R., et al.
Publicado: (2012)

Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2021)

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
por: Cornelissen, Robin, et al.
Publicado: (2014)

Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO
por: van Kooten, Job P, et al.
Publicado: (2022)

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
por: de Boer, Nadine L, et al.
Publicado: (2019)

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
por: Goey, S. H., et al.
Publicado: (1995)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
por: Trempolec, Natalia, et al.
Publicado: (2020)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
por: Nowak, A K, et al.
Publicado: (2002)

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
por: van Kooten, Job P, et al.
Publicado: (2022)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
por: de Goeje, Pauline L., et al.
Publicado: (2018)

How I treat malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

Experimental Model of Human Malignant Mesothelioma in Athymic Mice
por: Colin, Didier J., et al.
Publicado: (2018)

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
por: Beije, Nick, et al.
Publicado: (2017)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
por: Dumoulin, Daphne W., et al.
Publicado: (2020)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab
por: Richez, Christophe, et al.
Publicado: (2009)

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
por: Solheim, O. P., et al.
Publicado: (1992)

Mesothelioma Tumor Cells Modulate Dendritic Cell Lipid Content, Phenotype and Function
por: Gardner, Joanne K., et al.
Publicado: (2015)

PD-L1(+) lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients
por: Raniszewska, A., et al.
Publicado: (2020)

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
por: Dammeijer, Floris, et al.
Publicado: (2021)

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
por: van Meerbeeck, J., et al.
Publicado: (1996)

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
por: Belderbos, Robert A., et al.
Publicado: (2019)

Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
por: van Gulijk, Mandy, et al.
Publicado: (2018)

Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
por: de Boer, Nadine L., et al.
Publicado: (2019)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2q4mfmules3otglcvcubqf35um